The estimated Net Worth of Mordechai Friedman is at least $1.4 ezer dollars as of 14 December 2015. Mordechai Friedman owns over 5,000 units of Brainstorm Cell Therapeutics stock worth over $1,400 and over the last 13 years Mordechai sold BCLI stock worth over $0.
Mordechai has made over 1 trades of the Brainstorm Cell Therapeutics stock since 2015, according to the Form 4 filled with the SEC. Most recently Mordechai exercised 5,000 units of BCLI stock worth $3,750 on 14 December 2015.
The largest trade Mordechai's ever made was exercising 5,000 units of Brainstorm Cell Therapeutics stock on 14 December 2015 worth over $3,750. On average, Mordechai trades about 714 units every 0 days since 2011. As of 14 December 2015 Mordechai still owns at least 5,000 units of Brainstorm Cell Therapeutics stock.
You can see the complete history of Mordechai Friedman stock trades at the bottom of the page.
Mordechai's mailing address filed with the SEC is C/O BRAINSTORM CELL THERAPEUTICS, INC.,, 605 THIRD AVENUE, 34TH FLOOR, NEW YORK, NY, 10158.
Over the last 21 years, insiders at Brainstorm Cell Therapeutics have traded over $1,899,994 worth of Brainstorm Cell Therapeutics stock and bought 1,713,254 units worth $1,535,874 . The most active insiders traders include Corp. Accbt, Mike Frankenberger és International Holdings Ltd..... On average, Brainstorm Cell Therapeutics executives and independent directors trade stock every 145 days with the average trade being worth of $206,459. The most recent stock trade was executed by Ibrahim B. Dagher on 19 July 2024, trading 63,000 units of BCLI stock currently worth $22,050.
brainstorm cell therapeutics inc. (nasdaq:bcli), is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative disorders such as als (lou gehrig's disease), multiple sclerosis (ms) and parkinson’s disease (pd). these diseases have limited treatment options and as such represent unmet medical needs. nurown™ is brainstorm’s proprietary process for the propagation and differentiation of adult, autologous mesenchymal stem cells (msc) into neurotrophic factor (ntf)-secreting cells, and the transplantation of these specialized cells at or near the affected tissue site. our platform technology essentially converts mscs into living drug delivery system for ntfs. we have obtained proof-of-concept in a variety of animal models of neurodegenerative diseases, including parkinson's, huntington's, als, ms, and peripheral nerve injury. we have completed two single-arm clinical trials in als patients, conducted in israel, which have demonstr
Brainstorm Cell Therapeutics executives and other stock owners filed with the SEC include: